The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners
Latest from The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James)
Please check back later for more content.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5